Refine by
Sustainable Development Articles & Analysis
107 news found
Marine animals and microorganisms offer complex structural formations and bioactive compounds with potential applications in pharmaceutical development. Marine Extracts Alfa Chemistry's product line includes marine extracts which demonstrate its dedication to developing sustainable and efficient solutions. ...
The biodegradability and minimal toxicity of Polyolefins also make them attractive for the development of sustained-release formulations. Moreover, the tunable properties of Polyolefins allow modulation of drug release kinetics, resulting in precise control of the therapeutic dose. ...
Founded in 1963, in Maids Moreton, Vitalograph’s mission has remained unwavering over the past six decades – to improve the lives of people living with lung conditions through the development and manufacture of respiratory diagnostic solutions. As experts in pulmonary function, they also provide clinical drug trial services that enable the development of life-changing respiratory ...
Christian Rommel, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of Research and Development. “The current data underline that aflibercept 8 mg provides sustained disease control with greater and longer-lasting control of the underlying disease compared to Eylea in a fixed dosing ...
ByBayer AG
While T1D usually appears during childhood or adolescence, it can also develop in adults. CKD affects up to 40% of people with T1D. The prevalence of CKD due to T1D increased by 58.2% from 1990 to 2007 and by 21.7% from 2007 to 2017. ...
ByBayer AG
Fast Track Designation is intended to facilitate the development and expedite the review of drug candidates to treat serious medical conditions and fulfill unmet medical needs. ...
ByBayer AG
Treatment intervals can be further extended after the week 36 timepoint. Aflibercept 8 mg has been developed with the aim to extend intervals between injections without compromising vision gains and safety. ...
ByBayer AG
About aflibercept 8 mg Aflibercept 8 mg has been developed with the aim to increase intervals between injections without compromising vision gains. ...
ByBayer AG
Darolutamide, which is jointly developed by Bayer and Orion Corporation, is an oral androgen receptor inhibitor indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease and for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). ...
ByBayer AG
” Petro Terblanche, Afrigen Chief Executive Officer, declared: “The COVID-19 pandemic has shown that there is a pressing need to build sustainable capabilities in vaccine development and manufacturing in African and other LMICs. ...
ByeTheRNA
Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. ...
ByBayer AG
The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. ...
ByBayer AG
Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by Bayer and in the U.S. by Janssen Pharmaceuticals, Inc. (Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & ...
ByBayer AG
The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. ...
ByBayer AG
Aflibercept 8 mg is being jointly developed by Bayer and Regeneron. Regeneron maintains exclusive rights to Eylea and aflibercept 8 mg in the United States. ...
ByBayer AG
The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. ...
ByBayer AG
A key presentation highlights new clinical data on the novel development compound gadoquatrane, a next generation macrocyclic gadolinium-based contrast agent (GBCA) which is currently in Phase II of clinical development and planned to enter Phase III later this year. ...
ByBayer AG
The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. ...
ByBayer AG
“Today’s official closing of the acquisition of Blackford marks an important step in implementing our strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow,” said Gerd Krüger, President Radiology, Bayer. ...
ByBayer AG
Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. Despite guideline-directed therapies, patients with CKD and T2D remain at high risk of CKD progression and cardiovascular events. ...
ByBayer AG